

Florian van BÄmmel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8463691/publications.pdf>

Version: 2024-02-01

41
papers

7,121
citations

279798

23
h-index

265206

42
g-index

42
all docs

42
docs citations

42
times ranked

6183
citing authors

#	ARTICLE	IF	CITATIONS
1	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology, 2017, 67, 370-398.	3.7	3,803
2	Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. New England Journal of Medicine, 2005, 352, 2682-2695.	27.0	1,465
3	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology, 2017, 66, 1444-1453.	7.3	239
4	Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients â€“ FINITE study. Journal of Hepatology, 2017, 67, 918-924.	3.7	230
5	Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology, 2015, 61, 66-76.	7.3	204
6	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. Journal of Hepatology, 2018, 68, 1129-1136.	3.7	88
7	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. Journal of Hepatology, 2020, 72, 1088-1096.	3.7	75
8	Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology, 2018, 68, 839-847.	7.3	72
9	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. Journal of Hepatology, 2020, 73, 1037-1045.	3.7	69
10	Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut, 2018, 67, 2045-2053.	12.1	66
11	Ten millennia of hepatitis B virus evolution. Science, 2021, 374, 182-188.	12.6	64
12	T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 397-409.	3.7	59
13	Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. Journal of Infectious Diseases, 2018, 218, 1066-1074.	4.0	56
14	Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. Journal of Hepatology, 2014, 60, 928-933.	3.7	55
15	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. Journal of Hepatology, 2022, 76, 311-318.	3.7	48
16	Safety and effectiveness of up to 3 yearsâ€™ bulevirtide monotherapy in patients with HDV-related cirrhosis. Journal of Hepatology, 2022, 76, 464-469.	3.7	48
17	The times they are a-changing â€“ A refined proposal for finite HBV nucleos(t)ide analogue therapy. Journal of Hepatology, 2021, 75, 474-480.	3.7	46
18	Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. Clinical Infectious Diseases, 2021, 72, 202-211.	5.8	41

#	ARTICLE	IF	CITATIONS
19	Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B. Hepatology, 2018, 68, 397-400.	7.3	36
20	Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. Journal of Hepatology, 2021, 74, 283-292.	3.7	35
21	Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBsAg-negative chronic hepatitis B. Liver International, 2018, 38, 90-96.	3.9	31
22	A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV cure™. Journal of Hepatology, 2022, 77, 245-248.	3.7	29
23	Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver International, 2020, 40, 539-548.	3.9	24
24	Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. Journal of Viral Hepatitis, 2020, 27, 610-619.	2.0	21
25	Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. Hepatology Communications, 2021, 5, 1632-1648.	4.3	20
26	Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. Pathogens, 2022, 11, 517.	2.8	20
27	Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. Alimentary Pharmacology and Therapeutics, 2021, 53, 314-320.	3.7	19
28	Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 733-744.	3.7	18
29	Evolution of Adefovir-Resistant HBV Polymerase Gene Variants after Switching to Tenofovir Disoproxil Fumarate Monotherapy. Antiviral Therapy, 2012, 17, 1049-1058.	1.0	15
30	Association of HLA-DPA1 and HLA-DPB1 polymorphisms with spontaneous HBsAg seroclearance in Caucasians. Liver International, 2019, 39, 646-654.	3.9	12
31	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine, 2021, 70, 103521.	6.1	11
32	Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery. PLoS ONE, 2021, 16, e0254817.	2.5	10
33	Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis Registry. Liver International, 2021, 41, 1518-1522.	3.9	9
34	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2022, 20, 1343-1353.e16.	4.4	9
35	Low prevalence of occult hepatitis B virus infection in chronic haemodialysis and kidney transplant patients. Liver International, 2019, 39, 263-270.	3.9	7
36	Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis Registry. Hepatology Communications, 2022, 6, 2488-2495.	4.3	6

#	ARTICLE	IF	CITATIONS
37	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP Reports, 2021, 3, 100290.	4.9	5
38	Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. CardioVascular and Interventional Radiology, 2021, , 1.	2.0	5
39	Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	4
40	Final safety and efficacy results from a 106 real-world patients registry with an ascitesâ€mobilizing pump. Liver International, 2022, 42, 2247-2259.	3.9	4
41	Surrogate Markers for Hepatitis B Virus Covalently Closed Circular DNA. Seminars in Liver Disease, 2022, 42, 327-340.	3.6	1